Login
Register
Submit a Paper
Propose a Special lssue
Open Access
ARTICLE
ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells
* Department of Nephrology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China
† Department of Orthopaedics, General Hospital of Chinese People’s Liberation Army, Beijing, China
1
These authors provided equal contribution to this work.
Oncology Research 2016, 24(1), 65-72. https://doi.org/10.3727/096504016X14587366983838
Download PDFAbstract
Renal cell carcinoma (RCC) is the most common malignancy in the kidney in the world, and the 5-year overall survival for patients remains poor due to the lack of effective treatment strategies. Although ABT-737, as a Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic reagent, apoptosis induced by ABT-737 is often blocked in several types of cancer cells. This study investigated whether the combination of the small-molecule BH3 mimetic ABT-737 and the lysosome inhibitor chloroquine was an effective strategy for treating renal cancer cells. We found that the combination of ABT-737 and chloroquine synergistically decreased cell viability when compared to treatment with either single reagent. Cell apoptosis induced by a combined treatment was markedly inhibited by the caspase inhibitors z-DEVD-FMK and z-VAD-FMK. It was also inhibited by cathepsin inhibitor E-64 and CTSI (cathepsin inhibitor), which suggested that apoptosis was dependent on the cascade of caspase activation and cathepsins released from lysosomes. Furthermore, we found that ABT-737 could increase the cell level of ROS, which triggers cathepsin-mediated cell death and augments the role of chloroquine in cell death. So the combination of ABT-737 and chloroquine was an effective strategy for the treatment of renal cancer cells, and this combined strategy may widen the therapeutic window of ABT-737 and chloroquine as well as enhance the clinical efficacy of synergistic drug combinations.Keywords
Cite This Article
APA Style
Yin, P., Jia, J., Li, J., Song, Y., Zhang, Y. et al. (2016). ABT-737, a bcl-2 selective inhibitor, and chloroquine synergistically kill renal cancer cells. Oncology Research, 24(1), 65-72. https://doi.org/10.3727/096504016X14587366983838
Vancouver Style
Yin P, Jia J, Li J, Song Y, Zhang Y, Chen F. ABT-737, a bcl-2 selective inhibitor, and chloroquine synergistically kill renal cancer cells. Oncol Res. 2016;24(1):65-72 https://doi.org/10.3727/096504016X14587366983838
IEEE Style
P. Yin, J. Jia, J. Li, Y. Song, Y. Zhang, and F. Chen "ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells," Oncol. Res., vol. 24, no. 1, pp. 65-72. 2016. https://doi.org/10.3727/096504016X14587366983838
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
